[1] 刘率男,刘 泉,孙素娟,等. 二甲双胍对2型糖尿病KKAy小鼠胰岛β细胞功能的影响及初步作用机制探讨[J]. 药学学报,2014,49 (11): 1554-1562. [2] 程俊霖, 刘江慧, 胡云芳,等.DPPⅣ抑制剂对2型糖尿病的Ⅰ期临床研究[J]. 东南国防医药,2014,16(6):592-596. [3] 徐淑云,卞如濂,陈 修.药理实验方法学[M].3版.北京:人民卫生出版社, 2002:1006-1007. [4] De MI, Korom S, Van DJ,et al. CD26, let it cut or cut it down [J]. Immunol Today, 1999, 20(8): 367-375. [5] 杨 露,成 玮,丁长花,等.谷氨酰胺降低2型糖尿病患者血糖的机制探讨[J]. 东南国防医药,2015,17(2):127-129. [6] 师俊梅.妊娠期糖尿病患者的血糖控制效果对妊娠结局的影响[J]. 东南国防医药,2015,17(1):40-42. [7] Abd A, Tahrani MK, Piya AH, et al. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus [J]. Adv Ther, 2009, 26(3): 249-262. [8] Argyrakopoulou G, Doupis J. DPP4 inhibitors: from Sitagliptin monotherapy to the new Alogliptin-Pioglitazone combination therapy [J]. Adv Ther, 2009, 26(3): 272-280. [9] Kim SJ, Nian C, Doudet DJ, et al. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice [J]. Diabetes,2008,57(5): 1331-1339. [10] Furuta Y, Horiguchi M, Sugaru E, et al. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice[J]. Diabetes Obes Metab,2010,12(5): 421-430. [11] Yasushi K,Takayuki K,Youichi S. et al. Increased plasma dipeptidyl peptidase IV (DPP IV) activity and decreased DPP IV activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-Fat or high-sucrose diet [J].Biol Pharm Bull, 2009, 32(3): 463-467. [12] Jian Y, Campitelli J, Gang H, et al. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin [J]. Life Sci, 2007, 81(4): 272-279. [13] Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus[J]. Diabetologia, 2005, 48(6): 1168-1172. [14] McKillop AM, Duffy NA, Lindsay JR, et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36) amide degradation in type 2 diabetic subjects [J]. Diabetes Res Clin Pract, 2008, 79(1): 79-85. [15] Meneilly GS, Demuth HU, McIntosh CS, et al. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose [J]. Diabet Med, 2000, 17(5): 346-350. [16] Stefanovic V, Antic S, Mitic-Zlatkovic M, et al. Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin [J]. Diabetes Metab Res Rev, 1999, 15(6): 400-404. [17] Marguet D, Baggio I, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 [J]. Proc Natl Acad Sci, 2000, 97(12): 6874-6879. [18] 李益明.DPP-4抑制剂的独特作用机制:胰岛α、β细胞双调节作用[J].临床与药物,2014,11(7):21-23. [19] 郭 衔, 王 翼, 龙兆丰.口服降糖药二肽基肽酶Ⅳ(DPP-4)抑制剂的多器官保护作用[J].药学与临床研究,2014,22(6):524-526.